Abstract:Chimeric Antigen Receptor (CAR) T cell therapy has gained success in adoptive cell therapy for hematological malignancies. Although most CAR cell therapies in clinical trials or markets remain autologous, their acceptance has been limited due to issues like lengthy manufacturing, poor cell quality, and demanding cost. Consequently, "Off-the-shelf", universal CAR (UCAR) cell therapy has emerged. Current concerns with UCAR therapies revolve around side effects such as graft versus host disease (GVHD) and host versus graft response (HVGR). Preclinical research on UCAR cell therapies aims to enhance efficacy and minimize these side effects. Common approaches involve gene editing techniques to knock out T cell receptor (TCR), human leukocyte antigen (HLA), and CD52 expression to mitigate GVHD and HVGR risks. However, these methods carry drawbacks including potential genotoxicity of the edited cells. Most recently, novel editing techniques, such as epigenetic editing and RNA writer systems, have been developed to reduce the risk of GVHD and HVGR, allowing for multiplex editing at different sites. Additionally, incorporating more cell types into UCAR cell therapies, like T-cell subtypes (DNT, γδT, virus-specific T cells) and NK cells, can efficiently target tumors without triggering side effects. In addition, the limited efficacy of T cells and NK cells against solid tumors is being addressed through CAR-Macrophages. In summary, CAR cell therapy has evolved to accommodate multiple cell types while expanding applications to various diseases, including hematologic malignancies and solid tumors, which holds tremendous growth potential and is promised to improve the lives of more patients in the future.

Allogeneic CAR-T cells for cancer immunotherapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances

Current state of CAR-T therapy for T-cell malignancies

Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

Advances in Universal CAR-T Cell Therapy

Current progress in CAR-T cell therapy for tumor treatment

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

Universal CAR cell therapy: Challenges and expanding applications

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Recent updates on allogeneic CAR-T cells in hematological malignancies

Strategies for Overcoming Bottlenecks in Allogeneic CAR-T Cell Therapy

Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy